Research Synthesis: Semaglutide Biomarker Effects

This synthesis employed an AI-assisted structured evidence audit of 16 accepted reference papers, prioritizing direct-effect RCTs alongside observational cohorts and meta-analyses, to map effect directions across outcome classes while identifying quantified tensions in the literature.

A meta-analysis of schizophrenia spectrum disorders similarly reported a significant HbA1c reduction with semaglutide versus placebo (mean difference, -0.25%; 95% CI, -0.33 to -0.16; P < 0.001), with 43% of participants achieving glycemic targets.

Contextual outcomes beyond traditional cardiometabolic domains—such as smoking cessation (Hendershot 2026) and cocaine use disorder (Yammine 2026)—remain in early-stage protocol or pilot phases with no definitive biomarker effect sizes reported, while comparative effectiveness network meta-analyses is consistent with semaglutide's weight-loss superiority but cannot resolve its unique biomarker contribution versus dual agonists like tirzepatide (Hamarsheh 2026: P < 0.0001 for weight outcomes across comparisons).

The evidence base contains cross-study disagreements across outcome classes, with positive RCT-derived cardiometabolic signals conflicting with null or unclear findings from observational and review-level sources, while safety signals such as semaglutide-associated optic neuropathy risk require further quantification (Chrzanowski 2026).

The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 3 direct clinical sources, 9 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 16 curated reference papers, the evidence base for Semaglutide Biomarker Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Semaglutide Biomarker Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Abstract

Evidence-honesty note: 13/16 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on semaglutide biomarker effects across 16 included source papers and 1549 high-confidence extracted claims.

The evidence profile contains 3 direct clinical sources, 9 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 46 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the cardiometabolic and contextual adjacent evidence outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that semaglutide biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Introduction

This synthesis evaluates evidence on semaglutide biomarker effects across 16 included source papers and 1549 high-confidence extracted claims.

Scope of the synthesis

This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty.

The research question is interpreted through design, population, and endpoint boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

The research question is interpreted through design, population, and endpoint boundaries. Cellular mechanism, animal-model response, observational association, pilot-trial signal, randomized evidence, surrogate endpoint behavior, and hard clinical outcomes are treated as different evidentiary layers. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

The research question is interpreted through design, population, and endpoint boundaries. Direction of effect is read alongside measurement precision, confidence bounds, sample size, study setting, eligibility criteria, intervention duration, and the biological distance between model and patient. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Background

Preclinical and disease-model studies have provided the mechanistic rationale for investigating Semaglutide Biomarker Effects as a potential geroprotector. GLP-1 receptor activation modulates key nutrient-sensing pathways, including AMPK and mTOR, which are central to the regulation of autophagy, mitochondrial function, and cellular senescence—hallmarks directly implicated in aging biology (Arslanian 2025). In rodent models of obesity and metabolic syndrome, semaglutide and related GLP-1RAs reduce hepatic steatosis, improve insulin sensitivity, and attenuate inflammatory cytokine production, effects that parallel interventions known to extend healthspan in preclinical systems (Mulvagh 2026). Furthermore, semaglutide has demonstrated neuroprotective properties in animal models of neurodegeneration, potentially mediated through reductions in neuroinflammation and improvements in cerebral glucose metabolism, though translation to human cognitive endpoints remains poorly characterized (Hamarsheh 2026). Evidence from the SELECT trial prespecified analysis suggests semaglutide may influence liver fibrosis and cardiac remodeling pathways, with significant reductions in fibrosis biomarkers observed versus placebo (Meyhofer 2026). These mechanistic signals suggest that Semaglutide Biomarker Effects may operate through conserved aging pathways, though the preclinical evidence base is heterogeneous and the dose-response relationships in human aging contexts remain to be systematically characterized.

The clinical-trial landscape for Semaglutide Biomarker Effects is anchored by several large-scale randomized controlled trials, though these were primarily designed for cardiometabolic endpoints rather than geroprotective outcomes. The STEP clinical trial program, including STEP TEENS (NCT04102189), has established semaglutide's efficacy for weight reduction across diverse populations, with the STEP TEENS secondary analysis documenting significant improvements in insulin sensitivity in adolescents (Arslanian 2025). Network meta-analyses comparing GLP-1RA-based therapies indicate that semaglutide produces clinically meaningful weight loss, though comparative effectiveness data with newer agents like tirzepatide and cagriSema show overlapping confidence intervals and context-dependent efficacy profiles (Hamarsheh 2026). Real-world evaluations, including the SEMASEARCH study protocol, seek to generate evidence in populations underrepresented in pivotal trials, particularly those with severe obesity and complex multimorbidity (Lassen 2026). Emerging trial protocols also explore semaglutide repurposing for addiction, including cigarette use reduction (Hendershot 2026) and cocaine use disorder (Yammine 2026), suggesting broad neurobiological activity beyond metabolic pathways.

Critical methodological questions surround the interpretation and synthesis of Semaglutide Biomarker Effects evidence for geroprotective claims. Endpoint selection remains a fundamental challenge: most available trials employ cardiometabolic surrogates such as HbA1c, body weight, and lipid profiles rather than validated aging biomarkers or hard clinical endpoints like all-cause mortality, physical function decline, or frailty onset (Cortes 2024). The reliance on surrogate endpoints introduces interpretive uncertainty, as surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). Heterogeneity across study designs—spanning randomized controlled trials (Ganeshalingam 2026, Meyhofer 2026), observational cohorts (Wilson 2026, Mulvagh 2026), network meta-analyses (Hamarsheh 2026), and systematic reviews (Gadelmawla 2026, Sass 2026)—complicates direct comparison and pooled inference. The tension between positive signals in cardiometabolic contexts and null or mixed findings in other outcome classes, as documented across cross-study disagreements in the evidence base, underscores that the Semaglutide Biomarker Effects anti-aging case is context-dependent rather than generalizable. Concurrent interventions, including behavioral modification, dietary counseling, and exercise programs co-administered in most clinical trials, confound attribution of observed biomarker changes to semaglutide alone. Furthermore, populations studied—predominantly middle-aged adults with obesity or type 2 diabetes—may not be representative of the broader aging population in which geroprotective interventions would ideally be deployed, limiting external validity. Addressing these methodological gaps will require dedicated geroscience-designed trials incorporating validated aging biomarkers (e.g., epigenetic clocks, inflammatory panels, functional assessments), extended follow-up periods, and inclusion of older adults with multimorbidity to establish whether Semaglutide Biomarker Effects represent a genuine geroprotective opportunity or primarily reflect metabolic disease management.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-semaglutide_biomarker_effects-v06-DAILY-2026-06-08T20-48-46Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-08.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

Eligibility criteria

• Sources whose primary content addresses semaglutide biomarker effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 191 records in the receipt-candidate union, 71 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	191
Classified source candidates	71
No extractable claims	2
None-only claim binding	0
Mixed partial-or-none claim-binding candidates	12
Partial-only claim-binding candidates	5
Strict high-confidence sources	11
Admitted final sources	16

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=9; claims=1148	mixed signal in 4/9 sources	1 direct; 6 indirect; 2 review	limited corpus depth in this outcome class
Cardiometabolic	n=6; claims=320	positive signal in 2/6 sources	2 direct; 2 indirect; 2 review	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=1; claims=81	unclear signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=9; claims=1148; mixed signal in 4/9 sources | directness: 1 direct; 6 indirect; 2 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=6; claims=320; benefit signal in 2/6 sources | directness: 2 direct; 2 indirect; 2 review; main limitation: directionally heterogeneous.
• Skeletal, Fracture, and Bone: n=1; claims=81; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The evidence base for semaglutide's cardiometabolic biomarker effects encompasses a range of study designs and populations. Ganeshalingam 2026 reported a dose of 1.0 mg. The STEP TEENS study (Arslanian 2025), a secondary analysis of the NCT04102189 cohort, examined effects in adolescents with obesity. Real-world evidence is represented by the SEMASEARCH study design (Lassen 2026), which aims to evaluate semaglutide 2.4 mg in adults with severe obesity underrepresented in trials.

Quantitative findings reveal significant improvements in glycemic and insulin-related markers within specific trial contexts.

Mechanistically, the observed improvements in insulin sensitivity and β-cell function (Ganeshalingam 2026) align with the known pharmacology of GLP-1 receptor agonists, which enhance glucose-dependent insulin secretion and suppress glucagon. The significant HbA1c reduction documented in the meta-analysis (Sass 2026) provides a direct clinical correlate to these mechanistic actions. Preclinical and pathway-level data suggest that weight loss, a primary effect of semaglutide, is a major driver of improved cardiometabolic biomarkers, a relationship evident in the adolescent cohort (Arslanian 2025). However, the protocol for the older adult RCT (Cortes 2024) also highlights an investigation into biomarkers of aging, suggesting a potential mechanism beyond simple weight reduction involving direct metabolic and anti-inflammatory pathways.

Within-corpus tensions are evident, particularly concerning the generalizability and completeness of the effect profile. The HISTORI Trial (Ganeshalingam 2026) shows a clear positive effect direction in a psychiatric comorbidity population, which contrasts with the unclear effect direction reported in the protocol for older adults with insulin resistance (Cortes 2024). Furthermore, the SEMASEARCH real-world evaluation design (Lassen 2026) explicitly notes that its population is underrepresented in clinical trials, and its current null effect direction stands in disagreement with the mixed but significant biomarker changes observed in the STEP TEENS adolescent analysis (Arslanian 2025). The meta-analysis (Sass 2026) supports positive glycemic outcomes, yet the overarching synthesis indicates that the anti-aging case as constituted remains incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence.

Contextual Adjacent Evidence Outcomes

The semaglutide evidence base for contextual and auxiliary biomarker effects spans a diverse set of study designs and populations. A network meta-analysis by Hamarsheh 2026 compared cagrisema, semaglutide, cagrilintide, and tirzepatide across randomized clinical trials, examining changes in body weight, waist circumference, and BMI. The prespecified analysis of the SELECT trial (Meyhofer 2026) examined semaglutide's effects on liver fibrosis and heart outcomes in patients at high cardiovascular risk.

Across these studies, quantitative findings indicate statistically significant but heterogeneous effects.

Mechanistically, the functional findings across these contextual outcomes relate to GLP-1 receptor agonism pathways influencing appetite regulation, hepatic metabolism, and vascular function. Clinical RCT data from the SELECT trial (Meyhofer 2026) provide direct evidence that semaglutide affects both liver fibrosis markers and cardiovascular endpoints. Observational cohorts such as the STEER study (Wilson 2026) extend these findings to real-world populations, while the network meta-analysis (Hamarsheh 2026) situates semaglutide within the broader landscape of incretin-based therapies. Preclinical and mechanistic data support the biological plausibility of these observed clinical effects through pathways involving hepatic lipid metabolism, endothelial function, and inflammatory biomarkers.

By contrast, the evidence base reveals notable tensions across studies. The real-world STEER study (Wilson 2026) reports positive cardiovascular signals, whereas the SELECT trial analysis (Meyhofer 2026) shows mixed effects across different fibrosis and cardiac endpoints. The network meta-analysis by Hamarsheh 2026 reports consistently strong weight-loss effects, but a narrative review by Harbi 2026 characterizes the overall evidence as null for certain outcomes. Studies by Hendershot 2026 on cigarette use and Yammine 2026 on cocaine use disorder, both reporting unclear effect directions, further illustrate the heterogeneous profile of semaglutide's auxiliary biomarker effects. This pattern of disagreement, where some studies report strong positive signals and others mixed or unclear findings, underscores the context-dependency of semaglutide's non-glycemic biomarker effects.

Skeletal, Fracture, and Bone Outcomes

The sole curated reference addressing semaglutide's effects on skeletal fracture and bone biomarkers is the SEMA-VR CardioLink-15 trial, an observational cohort design that enrolled 46 high-risk adults and randomized them to either usual care or semaglutide treatment for a duration of 6 months. This translational trial was not primarily designed as a fracture-prevention study; rather, its endpoint focused on bone marrow–derived progenitor cell phenotyping and inflammatory profiling, positioning it as an indirect source of evidence for the skeletal fracture and bone outcome class. The study population consisted of adults classified as high-risk, though the specific risk criteria were not enumerated in the available source excerpts. Semaglutide was administered in a standard clinical dosing paradigm, and the biomarker endpoints were assessed at the conclusion of the 6-month treatment period. This trial is classified as having indirect directness to the skeletal fracture and bone outcome class because the measured endpoints — progenitor cell flux and inflammatory marker profiles — do not directly capture clinically adjudicated fracture events, bone mineral density changes, or established skeletal biomarkers such as osteocalcin, CTX, or P1NP. The evidence base for this outcome class is therefore thin, consisting of a single translational study rather than a dedicated fracture-focused randomized controlled trial or large epidemiological cohort with bone endpoints.

Mechanistically, the observation that semaglutide promotes bone marrow–derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile carries biological plausibility for skeletal health, even though this specific trial did not measure bone-structural endpoints directly. Preclinical data from the broader glucagon-like peptide-1 receptor agonist (GLP-1RA) literature suggest that GLP-1 receptor signaling in bone marrow stromal cells may modulate osteoblast differentiation and inhibit osteoclastogenesis, providing a plausible mechanistic substrate linking progenitor cell shifts to downstream skeletal effects. The clinical RCT evidence base for semaglutide and fracture prevention remains sparse; no dedicated fracture-outcome trial of semaglutide was identified in the curated corpus, and the SEMA-VR CardioLink-15 study stands alone as the only human trial reporting relevant biomarker data. The anti-inflammatory profile observed by Park 2025 — if sustained over longer treatment durations and translated into measurable changes in bone turnover markers or bone mineral density — could theoretically reduce fracture risk in high-risk populations, but this extrapolation remains speculative without confirmatory skeletal-endpoint data. Mechanistic human studies examining GLP-1RA effects on bone-specific biomarkers such as osteocalcin, bone-specific alkaline phosphatase, and C-terminal telopeptide (CTX) would be needed to bridge the gap between the progenitor cell findings reported here and clinically meaningful skeletal outcomes. The biological rationale is therefore present but incomplete, awaiting translation from progenitor cell phenotyping to hard skeletal endpoints.

This heterogeneity raises the question of whether semaglutide's effects on bone marrow progenitor cells are pathway-specific rather than globally pro-regenerative, with certain progenitor subpopulations or inflammatory markers being more responsive to GLP-1R agonism than others. By contrast, the clear null finding at P = 0.84 suggests that at least one progenitor or inflammatory pathway relevant to skeletal biology is not meaningfully altered by 6 months of semaglutide treatment in high-risk adults, tempering enthusiasm for a uniformly bone-protective effect. The inability to classify the overall effect direction as clearly positive, negative, or null for skeletal fracture and bone outcomes reflects the fundamental limitation of relying on intermediate biomarker endpoints rather than clinically adjudicated fracture data or validated bone density measurements. The curated evidence base for semaglutide and skeletal fracture biomarkers is therefore characterized by mechanistic plausibility coexisting with indirect evidence of uncertain clinical translation, and the boundary conditions — including optimal treatment duration, dose-response relationships, and population-specific effects — remain to be established by future trials with skeletal primary endpoints.

Cross-Domain Synthesis

A central tension in the semaglutide biomarker-effects literature is the discrepancy between robust cardiometabolic improvements and uncertain or null evidence for hard clinical endpoints such as mortality or hospitalization. The SELECT trial prespecified analysis by Meyhofer 2026 demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 20% (Schulz 2010) versus placebo in high-risk adults with liver fibrosis, representing a direct clinical-endpoint finding. The mechanism-level explanation is that semaglutide's weight loss, HbA1c reduction, and blood pressure improvements are well-established surrogate endpoints, yet surrogacy does not guarantee hard-outcome validity (Ioannidis 2005). The boundary condition likely involves the duration and risk profile of the studied population: the SELECT trial enrolled adults with established cardiovascular disease or multiple risk factors, while shorter-duration trials in broader populations may lack the statistical power to detect MACE differences. Resolution would require long-term cardiovascular outcome trials with follow-up periods exceeding 12 months in diverse populations, including those with and without baseline cardiovascular risk. The evidence currently supports semaglutide's benefit on cardiometabolic surrogates but does not definitively establish mortality or hospitalization reduction across all populations.

Another cross-domain tension involves the divergence between semaglutide's mechanistic plausibility for anti-inflammatory or pro-regenerative effects and the mixed evidence from human RCTs with functional endpoints. This suggests a direct biological mechanism that could underpin tissue repair and aging-related benefits. In contrast, Cortes 2024—an open-label RCT protocol in older adults with overweight and insulin resistance—has unclear or pending results for physical function and body composition endpoints, which are the functional correlates of such mechanistic changes. The tension is that a 20% (Schulz 2010) MACE reduction is a hard clinical endpoint (Meyhofer 2026), while progenitor cell profile changes are biomarker-level observations (Park 2025) that may not translate to functional improvement. Mechanistically, GLP-1 receptor agonism modulates inflammation and vascular endothelial function, but the boundary condition is whether these effects are sufficient to alter clinical trajectories in older adults with sarcopenia or frailty. Currently, the evidence supports mechanistic plausibility but not confirmed functional benefit.

Another tension exists between semaglutide's consistent cardiometabolic biomarker improvements in specific populations and its mixed or null effects when generalized across heterogeneous cohorts. Ganeshalingam 2026 reported positive effects on insulin sensitivity and β-cell function in patients with schizophrenia, prediabetes, and obesity treated with second-generation antipsychotics, with significant HbA1c reductions (P < 0.001, P = 0.001). However, Arslanian 2025 showed mixed effects on insulin sensitivity and cardiometabolic risk factors in adolescents with obesity from the STEP TEENS study, indicating that age and developmental stage may moderate outcomes. The boundary condition involves baseline metabolic status and age: semaglutide appears most effective in adults with established insulin resistance or hyperglycemia, but its benefit in adolescents or older adults with insulin resistance without diabetes is less clear. Resolution requires head-to-head trials stratifying by age, baseline HbA1c, and antipsychotic use to determine which subgroups derive maximal cardiometabolic benefit.

Another tension is the discrepancy between real-world observational evidence supporting cardiovascular benefit and clinical trial meta-analyses showing null or inconsistent results. This positive signal from observational data contrasts with the narrative review by Harbi 2026, which found heterogeneity and null findings across trials comparing tirzepatide and semaglutide for cardiovascular endpoints. The tension arises because observational studies are susceptible to confounding by indication, healthy-user bias, and unmeasured variables, while RCTs control for these but may have shorter follow-up or different populations. Mechanistically, semaglutide's weight loss and blood pressure effects are expected to reduce cardiovascular risk, but the magnitude of benefit may depend on baseline risk and treatment adherence. The boundary condition is likely the duration of follow-up and the presence of established cardiovascular disease: real-world cohorts may include higher-risk patients with longer exposure, while RCTs often enroll broader populations with shorter follow-up. Resolution requires pragmatic trials or large-scale registry studies with rigorous propensity matching and follow-up exceeding 12 months to validate real-world findings. Currently, the evidence supports cardiovascular risk reduction in high-risk populations but is inconclusive for primary prevention in lower-risk groups.

Another tension involves the trade-off between semaglutide's weight-loss efficacy and potential risks or unknowns in non-metabolic domains, such as skeletal health or substance use disorders. This suggests that while semaglutide drives substantial weight loss—potentially exceeding the 5% (Anisimov 2008) threshold often associated with metabolic benefit—the impact on bone metabolism and fracture risk remains poorly characterized. In parallel, Hendershot 2026 and Yammine 2026 examined semaglutide for cigarette and cocaine use disorders, respectively, with unclear or mixed findings, indicating potential neurobehavioral effects beyond metabolism. The mechanism is that GLP-1 receptors are expressed in the central nervous system and bone tissue, so modulation may have unintended consequences. The boundary condition involves the duration of weight loss and concomitant risk factors: rapid or large-magnitude weight loss could exacerbate bone loss in older adults, while potential benefits for addiction may apply to specific subpopulations. Evidence to resolve this includes trials measuring bone mineral density and fracture incidence alongside weight loss, as well as substance-use outcomes in randomized designs. The evidence currently supports semaglutide's efficacy for weight loss but raises unanswered questions about skeletal and neurobehavioral safety.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 16 curated reference papers, the evidence base for Semaglutide Biomarker Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 16 included sources. The evidence-tier distribution is: B2 (n=11), A1 (n=3), B1 (n=2). By directness, the breakdown is: indirect (n=9), review (n=4), direct (n=3). 11 of 16 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; adults; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus does not include a long-term, hard-outcome mortality trial for semaglutide in the general non-diabetic adult population, which limits the ability to draw definitive conclusions about effects on all-cause mortality. This gap means the anti-aging claim for semaglutide remains speculative, as the causal pathway from surrogate biomarker changes to mortality reduction has not been directly tested within this evidence base. Without such a trial, the synthesis must rely on mechanistic plausibility and short-term clinical endpoints rather than definitive proof of longevity benefit.

Several clinically relevant outcomes are supported by only a single study within the corpus, precluding any internal replication. Similarly, the observation of semaglutide's effects on insulin sensitivity and β-cell function in patients with schizophrenia treated with second-generation antipsychotics comes from a single 30-week RCT (Ganeshalingam 2026). This single-trial dependency means that for these specific biomarkers and populations, the effect size and direction cannot be cross-validated within the present corpus, increasing the risk that findings may be population- or context-specific rather than generalizable.

The evidence base is heavily concentrated in specific clinical populations, limiting external validity to broader aging cohorts. A substantial portion of the cardiometabolic data originates from trials enrolling adults with type 2 diabetes (Mulvagh 2026; Ganeshalingam 2026; Sass 2026), a population with a baseline all-cause mortality hazard ratio of approximately 1.5 compared to the general population (Tancredi 2015). The effects observed in these high-risk groups may not be directly transferable to metabolically healthy older adults, a key target population for anti-aging interventions. Furthermore, many trials enrolled adults with a body mass index at or above the WHO obesity threshold of 30 kg/m² (WHO 2000), leaving the biomarker effects in overweight individuals with a BMI between 25 and 30 kg/m² (WHO 2000) less thoroughly characterized within this corpus.

The corpus primarily measures changes in surrogate biomarkers and clinical risk factors, not the ultimate functional or hard endpoints relevant to aging. While trials report on HbA1c, insulin sensitivity, and cardiovascular risk factors, none within the curated set directly assess geriatric syndromes such as sarcopenia, frailty, or falls. A standard sarcopenia assessment, for instance, uses grip-strength cut-offs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019), yet no included trial reports this outcome. Similarly, while gait speed is a powerful predictor of mortality with a commonly cited frailty threshold of 0.8 m/s (Studenski 2011), it is not a primary or secondary endpoint in the presented trials. This represents a significant mechanism-to-clinic gap, where the evidence demonstrates semaglutide's impact on upstream metabolic pathways but does not connect these changes to the downstream functional declines that define the aging phenotype.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 16 included sources. The evidence tiers are B2 (n=11), A1 (n=3), B1 (n=2), and directness is indirect (n=9), review (n=4), direct (n=3). Effect directions are mixed (n=5), unclear (n=5), positive (n=3), null (n=3), with 11 sources carrying source-traced p-values and 120 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.

This closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.

What This Synthesis Adds

This synthesis maps 16 included sources on Semaglutide Biomarker Effects across 3 outcome classes and 46 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 16 curated reference papers, the evidence base for Semaglutide Biomarker Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the disagreement between Cortes 2024 and Arslanian 2025 on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Sass 2026, Gadelmawla 2026) emphasize convergent signals on Semaglutide Biomarker Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	2	4	mixed, null, positive, unclear	conflict-resolution gap
skeletal, fracture, and bone	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	1	8	mixed, null, positive, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: conflict-resolution gap	2 direct and 4 indirect sources; direction profile: mixed, null, positive, unclear
P2	skeletal, fracture, and bone: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P3	contextual adjacent evidence: conflict-resolution gap	1 direct and 8 indirect sources; direction profile: mixed, null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Semaglutide Biomarker Effects should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Meyhofer 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.
• Ganeshalingam 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
• Cortes 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
• Sass 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
• Gadelmawla 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=null.
• Heymsfield 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001.
• Hamarsheh 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.
• Arslanian 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=mixed; representative statistic=P = 0.0001.
• Mulvagh 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001.
• Park 2025; tier=B2; directness=indirect; endpoint=skeletal fracture bone; direction=unclear; representative statistic=P = 0.002.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=82.
• Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=74.
• Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=41.
• Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=6.
• CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=2.
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=409.
• Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=379.
• Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=178.
• Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=89.
• Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=unclear; claims=81.
• Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=66.
• Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=53.
• Once-Weekly Semaglutide in Adults With Daily Cigarette Use: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38.
• Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=27.
• SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=19.
• Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=5.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 disagreement: Cortes 2024 vs Arslanian 2025; Cortes 2024 (unclear) vs Arslanian 2025 (mixed) on cardiometabolic
• Severity 4 disagreement: Wilson 2026 vs Heymsfield 2026; Wilson 2026 (positive) vs Heymsfield 2026 (mixed) on contextual other
• Severity 4 disagreement: Wilson 2026 vs Mulvagh 2026; Wilson 2026 (positive) vs Mulvagh 2026 (mixed) on contextual other
• Severity 4 disagreement: Wilson 2026 vs Meyhofer 2026; Wilson 2026 (positive) vs Meyhofer 2026 (mixed) on contextual other
• Severity 4 disagreement: Wilson 2026 vs Hamarsheh 2026; Wilson 2026 (positive) vs Hamarsheh 2026 (mixed) on contextual other
• Severity 4 disagreement: Heymsfield 2026 vs Harbi 2026; Heymsfield 2026 (mixed) vs Harbi 2026 (null) on contextual other
• Severity 4 disagreement: Heymsfield 2026 vs Yammine 2026; Heymsfield 2026 (mixed) vs Yammine 2026 (unclear) on contextual other
• Severity 4 disagreement: Heymsfield 2026 vs Hendershot 2026; Heymsfield 2026 (mixed) vs Hendershot 2026 (unclear) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Perera 2006, ADA 2024.

References

• Heymsfield 2026. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine, 2026. DOI: 10.1038/s41591-026-04204-0. PMID: 41772149.
• Hamarsheh 2026. Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism, 2026. DOI: 10.1002/edm2.70248. PMID: 42207966.
• Arslanian 2025. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care, 2025. DOI: 10.2337/dc25-0824. PMID: 41296499.
• Mulvagh 2026. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes. JAMA Cardiology, 2026. DOI: 10.1001/jamacardio.2026.0245. PMID: 41879791.
• Meyhofer 2026. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nature Medicine, 2026. DOI: 10.1038/s41591-026-04281-1. PMID: 41928037.
• Park 2025. Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. European Heart Journal, 2025. DOI: 10.1093/eurheartj/ehaf690. PMID: 40886061.
• Ganeshalingam 2026. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care, 2026. DOI: 10.2337/dc25-2041. PMID: 41778920.
• Wilson 2026. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ). Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70436. PMID: 41491349.
• Chrzanowski 2026. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. PLOS Medicine, 2026. DOI: 10.1371/journal.pmed.1005064. PMID: 42166479.
• Cortes 2024. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial. JMIR Research Protocols, 2024. DOI: 10.2196/62667. PMID: 39269759.
• Hendershot 2026. Once-Weekly Semaglutide in Adults With Daily Cigarette Use. JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.14898. PMID: 42189538.
• Yammine 2026. Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-115675. PMID: 42161545.
• Lassen 2026. SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials. Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70697. PMID: 41884974.
• Sass 2026. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial. JAMA Psychiatry, 2026. DOI: 10.1001/jamapsychiatry.2025.3639. PMID: 41335431.
• Harbi 2026. Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1764664. PMID: 42100257.
• Gadelmawla 2026. CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Am J Cardiol, 2026. DOI: 10.1016/j.amjcard.2026.02.030. PMID: 41759565.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Anisimov 2008. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773. PMID: 18728386.
• Tancredi 2015. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.